Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00361374 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT00361374: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00361374 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 196 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00361374, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
This study examines the difference in the effectiveness of two natural compounds, eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major depressive disorder. Both types of omega-3 fatty acids are commonly found in fish oils. It is believed that a deficiency in these omega-3 fatty acids may lead to the development of major depression.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT docosahexaenoic acid
- DIETARY_SUPPLEMENT eicosapentaenoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2006-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00361374
The ClinicalTrials.gov registry entry for NCT00361374 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00361374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00361374 about?
NCT00361374 is a clinical study titled "Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression". This study examines the difference in the effectiveness of two natural compounds, eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major depressive disorder. Both types of omega-3 fatty acids are commonly found in fish oils. It is believed that a deficiency in these ome...
What is the current status of trial NCT00361374?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2006-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00361374?
The interventions under investigation include: Placebo (DRUG), docosahexaenoic acid (DIETARY_SUPPLEMENT), eicosapentaenoic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00361374?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.